MannKind Newsroom

Analysts Have Conflicting Sentiments on These Healthcare Companies: Cigna (CI), Hims & Hers Health (HIMS) and MannKind (MNKD)

TipRanksNov 6 16:13

Leerink Partners Initiates MannKind(MNKD.US) With Buy Rating, Announces Target Price $8

Futu NewsSep 10 06:31

MannKind Price Target Announced at $8.00/Share by Leerink Partners

Dow JonesSep 9 20:56

MannKind Analyst Ratings

BenzingaAug 28 21:03

Oppenheimer Maintains MannKind(MNKD.US) With Buy Rating, Raises Target Price to $12

Futu NewsAug 28 20:33

Oppenheimer Reaffirms Their Buy Rating on MannKind (MNKD)

TipRanksAug 28 20:22

MannKind's Strong Q2 Performance and Promising Pipeline Merit a Buy Rating

TipRanksAug 9 18:04

Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Envista Holdings (NVST) and Soleno Therapeutics (SLNO)

TipRanksAug 8 20:25

MannKind (MNKD) Gets a Hold From RBC Capital

TipRanksAug 8 20:23

MannKind Analyst Ratings

BenzingaJun 14 01:42

Rodman & Renshaw Initiates Coverage On MannKind With Buy Rating, Announces Price Target of $8

BenzingaJun 14 01:42

Oppenheimer Remains a Buy on MannKind (MNKD)

TipRanksMay 10 20:00

MannKind Buy Rating Affirmed by Analyst Thomas Smith on Strong Revenue Growth and Promising Clinical Developments

TipRanksMay 10 13:30

MannKind Analyst Ratings

BenzingaMay 9 23:00

Analysts Offer Insights on Healthcare Companies: LENZ Therapeutics (LENZ), MannKind (MNKD) and Aquestive Therapeutics (AQST)

TipRanksMay 9 18:51

Analysts Offer Insights on Healthcare Companies: MannKind (MNKD), Vertex Pharmaceuticals (VRTX) and Korro Bio (KRRO)

TipRanksApr 9 10:35

MannKind Analyst Ratings

BenzingaMar 15 22:55

MannKind's Strong Q4 Financials and Therapeutic Portfolio Potential Merit a Buy Rating

TipRanksMar 1 14:06

Cantor Fitzgerald Reiterates Overweight on MannKind, Maintains $6.5 Price Target

BenzingaFeb 29 00:22

MannKind Corporation: Strong Growth and Clinical Advancements Prompt Buy Rating

TipRanksFeb 28 21:55